Abstract: Ｏｂｊｅｃｔｉｖｅ：To observe the antihypertensive effect and safety of sacubitril／valsartan(SV)in maintenance hemodialysis (MHD) patients with hypertension.
Ｍｅｔｈｏｄｏｌｏｇｙ：In a selfcontrol study, 31 cases of hypertensive MHD patients treated with SV in Blood Purification Center of the First Affiliated Hospital of Zhengzhou University were selected, including 21 patients with refractory hypertension.Among the 31 patients,11 patients changed angiotensin receptor blockers (ARB) to SV.Blood pressure, blood routine, blood biochemistry were analyzed before and after treatment.
Ｒｅｓｕｌｔｓ：The antihypertensive effects of 31 patients were as follows: 4 weeks and 12 weeks after taking SV,systolic blood pressure(SBP)before HD decreased compared with that before treatment.The SBP during HD and after HD all decreased compared with that before treatment at 1 week, 4 weeks and 12 weeks after treatment.12 weeks after the treatment,the diastolic blood pressure(DBP) before HD was lower than that before treatment.At 1 week, 4 weeks and 12 weeks after treatment, DBP during and after HD all decreased compared with that before treatment (P<005).Aftertreatment,defined daily dose of other antihypertension drugs decreased ［249±158 vs 342±181,P<005］. The blood pressure of before,during and after HD of 11 patients who changed ARB to SV also decreased at 1 week, 4 weeks and 12 weeks after treatment. No adverse reactions related to SV were found during the treatment.
Ｃｏｎｃｌｕｓｉｏｎ：The comination of SV is a safe and effective therapy of hypertension in MHD patients.